ABB  Vol.4 No.1 , January 2013
Survivin promoter rs9904341 polymorphism is associated with tumor stage and grade in patients with bladder cancer
ABSTRACT
Survivin is an inhibitor of apoptosis protein and also plays a important role in the development of several malignancies. To investigate the association between survivin promoter 31 G/C (rs9904341) polymorphism and bladder cancer (BC) risk. A total of 200 pathologically confirmed BC cases and 200 unrelated cancer-free controls were recruited in Chiayi Christian Hospital from August 2002 to May 2009. Polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method was used to determine the 31 G/C polymorphism at survivin promoter region. There was a significant difference in the frequency distribution of survivin promoter 31 G/C polymorphism in BC cases as compared to controls. Among BC cases, individuals with the C/C genotype of survivin promoter have a significantly higher prevalence of invasive (T2-T4) or high-grade (G2-G3) tumors as compared to those who carried the G/G genotype. In conclusion, our findings suggest that the survivin promoter 31 G/C polymorphism was not only associated with clinical stage and pathological grade but also involved in the development of bladder cancer.

Cite this paper
Huang, Z. , Chiang, Y. , Tung, M. , Wu, C. , Chen, K. , Huang, M. , Wang, Y. and Shen, C. (2013) Survivin promoter rs9904341 polymorphism is associated with tumor stage and grade in patients with bladder cancer. Advances in Bioscience and Biotechnology, 4, 1-5. doi: 10.4236/abb.2013.41001.
References
[1]   Melet, A., et al. (2008) Apoptotic pathways in tumor progression and therapy. Advances in Experimental Medicine and Biology, 615, 47-79. doi:10.1007/978-1-4020-6554-5_4

[2]   Reed, J.C. et al. (2001) The Survivin saga goes in vivo. The Journal of Clinical Investigation, 108, 965-969. doi:10.1172/JCI14123

[3]   Sah, N.K., et al. (2006) Structural, functional and therapeutic biology of survivin. Cancer Letters, 244, 164-171. doi:10.1016/j.canlet.2006.03.007

[4]   Duffy, M.J., et al. (2007) Survivin: A promising tumor biomarker. Cancer Letters, 249, 49-60. doi:10.1016/j.canlet.2006.12.020

[5]   Shen, C.H., et al. (2007) Inducible nitric oxide synthase promoter poly-morphism, cigarette smoking, and urothelial carcinoma risk. Urology, 69, 1001-1006. doi:10.1016/j.urology.2007.02.028

[6]   Margulis, V., et al. (2008) Survivin: a promising biomarker for detection and prognosis of bladder cancer. World Journal of Urology, 26, 59-65. doi:10.1007/s00345-007-0219-y

[7]   Karam, J.A., et al. (2007) Survivin expression in patients with non-muscle-invasive urothelial cell carcinoma of the bladder. Urology, 70, 482-486. doi:10.1016/j.urology.2007.05.009

[8]   Ponnelle, T., et al. (2005) Cellular localisation of survivin: Impact on the prognosis in colorectal cancer. Journal of Cancer Re-search and Clinical Oncology, 131, 504-510. doi:10.1007/s00432-005-0682-z

[9]   Ulukus, E.C., et al. (2007) Survivin expression in non-small-cell lung carcinomas: Correlation with apoptosis and other apoptosis-related proteins, clinicopathologic prognostic factors and prognosis. Applied Immunohisto-chemistry & Molecular Morphology, 15, 31-37. doi:10.1097/01.pai.0000201808.35931.78

[10]   Lin, C.Y., et al. (2005) Survivin expression predicts poorer progno-sis in patients with areca quid chewing-related oral squamous cell carcinoma in Taiwan. Oral Oncology, 41, 645-654. doi:10.1016/j.oraloncology.2005.02.009

[11]   Smith, S.D., et al. (2001) Urine detection of survivin and diagnosis of bladder cancer. Journal of the American Medical Association, 285, 324-328. doi:10.1001/jama.285.3.324

[12]   Shariat, S.F., et al. (2004) Urine detection of survivin is a sensitive marker for the noninvasive diagnosis of bladder cancer. Journal of Urology, 171, 626-630. doi:10.1097/01.ju.0000107826.78479.90

[13]   Swana, H.S., et al. (1999) Tumor content of the antiapoptosis molecule survivin and recurrence of bladder cancer. The New England Journal of Medicine, 341, 452-453. doi:10.1056/NEJM199908053410614

[14]   Ku, J.H., et al. (2004) Expression of survivin, a novel inhibitor of apoptosis, in superficial transitional cell carcinoma of the bladder. Journal of Urology, 171, 631-635. doi:10.1097/01.ju.0000106082.44786.3b

[15]   Chiou, S.K., et al. (2003) Survivin—An anti-apoptosis protein: Its biological roles and implications for cancer and beyond. Med Sci Monit, 9, PI25-P129.

[16]   Li, F., et al. (1998) Control of apoptosis and mitotic spindle checkpoint by survivin. Nature, 396, 580-584. doi:10.1038/25141

[17]   Gonul, I.I., et al. (2007) Comparison of 1998 WHO/ ISUP and 1973 WHO classifications for interobserver variability in grading of papillary urothelial neoplasms of the bladder. Pathological evaluation of 258 cases. Urology International, 78, 338-344. doi:10.1159/000100839

[18]   Bircan, S., et al. (2004) Comparison of WHO 1973, WHO/ISUP 1998, WHO 1999 grade and combined scoring systems in evaluation of bladder carcinoma. Urology International, 73, 201-208. doi:10.1159/000080826

[19]   Tan, T.T., et al. (2008) Therapeutic targeting of death pathways in cancer: Mechanisms for activating cell death in cancer cells. Advances in Experimental Medicine and Biology, 615, 81-104. doi:10.1007/978-1-4020-6554-5_5

[20]   Coppola, J.M., et al. (2008) Noninvasive imaging of apoptosis and its application in cancer therapeutics. Clinical Cancer Research, 14, 2492-2501. doi:10.1158/1078-0432

[21]   Borbély, A.A., et al. (2007) Survivin promoter polymerphism and cervical carcino-genesis. Journal of Clinical Pathology, 60, 303-306. doi:10.1136/jcp.2006.037804

[22]   Jang, J.S., et al. (2008) Polymorphisms in the survivin gene and the risk of lung cancer. Lung Cancer, 60, 31-39. doi:10.1016/j.lungcan.2007.09.008

[23]   Wagner, M., et al. (2008) Epigenetic and genetic analysis of the survivin promoter in acute myeloid leukemia. Leu- kemia Research, 32, 1054-1060. doi:10.1016/j.leukres.2007.11.013

[24]   Cheng, Z.J., et al. (2008) Correlation of ?31G/C Polymorphisms of Survivin Promoter to Tumorigenesis of Gastric Carcinoma. Ai Zheng, 27, 258-263. doi:10.3760/cma.j.issn.1673-422X

[25]   Xu, Y., et al. (2004) A mutation found in the promoter region of the human survivin gene is correlated to over- expression of survivin in cancer cells. DNA and Cell Biology, 23, 527-537. doi:10.1089/1044549041939278

[26]   Hoffman, W.H., et al. (2002) Transcriptional repression of the anti-apoptotic survivin gene by wild type p53. The Journal of Biological Chemistry, 277, 3247-3257. doi:10.1074/ jbc.M106643200

[27]   Pina-Cabral, L., et al. (2007) Detection of survivin mRNA in urine of patients with superficial urothelial cell carcinomas. Clinical and Translational Oncology, 9, 731-736. doi:10.1007/s12094-007-0130-4

[28]   Schultz, I.J., et al. (2003) Survivin mRNA expression is elevated in malignant urothelial cell carcinomas and predicts time to re-currence. Anticancer Research, 23, 3327- 3331. doi:10.1111/j.1365-2567.2008.02826.x

[29]   Ohsawa, I., et al. (2004) Detection of urine survivin in 40 patients with bladder cancer. Journal of Nippon Medical School, 71, 379-383. doi:10.1272/jnms.71.379

[30]   Wang, H., et al. (2004) The expression and significance of survivin mRNA in urinary bladder carcinomas. Journal of Cancer Research and Clinical Oncology, 130, 487-490. doi:10.1007/s00432-004-0561-z

[31]   Srivastava, K., et al. (2012) Survivin promoter-31G/C (rs9904341) poly-morphism and cancer susceptibility: A meta-analysis. Molecular Biology Reports, 39, 1509-1516. doi:10.1007/s11033-011-0889-9

[32]   Wang, X., et al. (2012) Association between survivin ?31G > C promoter polymorphism and cancer risk: A meta-analysis. European Journal of Human Genetics, 20, 790-795. doi:10.1038/ejhg.2011.276

 
 
Top